摘要
目的分析多重用药冠心病患者出现生氯吡格雷抵抗(CR)的影响因素.方法回顾性分析2018年1月~2019年12月我院收治的70例冠心病患者临床资料.根据血栓弹力图检测结果分为抵抗组(n=28)和无抵抗组(n=42).统计患者的一般资料、实验室指标等,分析多重用药冠心病患者出现CR的影响因素.结果抵抗组TC、FBG水平、多重用药≥7种占比高于无抵抗组,差异有统计学意义(P<0.05);经Logistic多因素分析发现,TC≥5.17mmol/L、FBG≥5.60mmol/L、多重用药≥7种是多重用药冠心病患者出现CR的危险因素(OR>1,P<0.05).结论TC≥5.17mmol/L、FBG≥5.60mmol/L、多重用药≥7种是多重用药冠心病患者出现CR的危险因素,因而临床用药时进行个性化调整治疗方法,提高氯吡格雷的疗效,降低不良风险事件.
Objective To analyze the influencing factors of clopidogrel resistance(CR)in coronary heart disease patients with polypharmacy.Methods The clinical data of 70 patients with coronary heart disease who admitted in the hospital from January 2018 to December 2019 were retrospectively analyzed.The patients were divided into resistance group(n=28)and no-resistance group(n=42)according to the results of thrombelastogram.The general data and laboratory indicators of patients were recorded,and the influencing factors of CR in coronary heart disease patients with polypharmacy were analyzed.Results The TC,FBG levels and the proportion of polypharmacy 7 kinds in the resistance group and were higher than those in the no-resistance group,and the difference was statistically significant(P<0.05);Logistic multivariate analysis found that TC^5.17mmol/L,FBG≥5.60mmol/L,polypharmacy7 kinds were the risk factors for CR in coronary heart disease patients with polypharmacy(OR>1,P<0.05).Conclosion TC≥5.17mmol/L,FBG 5.60mmol/L,polypharmacy 7 kinds are the risk factors for CR in coronary heart disease patients with polypharmacy.Therefore,it is necessary to carry out personalized adjustment of the treatment method when clinical medication,so as to improve the efficacy of clopidogrel and reduce the adverse risk events.
出处
《首都食品与医药》
2020年第20期67-68,共2页
Capital Food Medicine
关键词
冠心病
多重用药
氯吡格雷抵抗
coronary heart disease
polypharmacy
clopidogrel resistance
